$4.9812
-0.2788[-5.30%]
At close: Apr 22
$4.9812
0[0.00%]
After Hours: 4:12PM EDT
Black Diamond Therapeutic
(NASDAQ:BDTX)Black Diamond Therapeutic Stock (NASDAQ:BDTX), Analyst Ratings, Price Targets, Predictions
Black Diamond Therapeutics Inc has a consensus price target of $12.25, established from looking at the 15 latest analyst ratings. The last 3 analyst ratings were released from Wedbush, HC Wainwright & Co., and Wedbush on April 8, 2024, March 18, 2024, and March 13, 2024. With an average price target of $12.67 between Wedbush, HC Wainwright & Co., and Wedbush, there's an implied 154.29% upside for Black Diamond Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
HC Wainwright & Co.
Piper Sandler
Stifel
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Black Diamond Therapeutic
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/08/2024 | BDTX | Buy Now | Black Diamond Therapeutic | $4.98 | 221.21% | Wedbush | Robert Driscoll | $10 → $16 | Maintains | Outperform | Get Alert |
| 03/18/2024 | BDTX | Buy Now | Black Diamond Therapeutic | $4.98 | 140.91% | HC Wainwright & Co. | Robert Burns | $11 → $12 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2024 | BDTX | Buy Now | Black Diamond Therapeutic | $4.98 | 100.75% | Wedbush | Robert Driscoll | → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 11/22/2023 | BDTX | Buy Now | Black Diamond Therapeutic | $4.98 | 120.83% | HC Wainwright & Co. | Robert Burns | → $11 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | BDTX | Buy Now | Black Diamond Therapeutic | $4.98 | 100.75% | Wedbush | Robert Driscoll | → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 07/14/2023 | BDTX | Buy Now | Black Diamond Therapeutic | $4.98 | 120.83% | Piper Sandler | Joseph Catanzaro | → $11 | Initiates | → Overweight | Get Alert |
| 06/30/2023 | BDTX | Buy Now | Black Diamond Therapeutic | $4.98 | 100.75% | Stifel | Bradley Canino | $2 → $10 | Upgrade | Hold → Buy | Get Alert |
| 06/28/2023 | BDTX | Buy Now | Black Diamond Therapeutic | $4.98 | 120.83% | HC Wainwright & Co. | Robert Burns | → $11 | Upgrade | Neutral → Buy | Get Alert |
| 06/27/2023 | BDTX | Buy Now | Black Diamond Therapeutic | $4.98 | -59.85% | Stifel | Bradley Canino | → $2 | Reiterates | Hold → Hold | Get Alert |
| 06/27/2023 | BDTX | Buy Now | Black Diamond Therapeutic | $4.98 | 100.75% | Wedbush | Robert Driscoll | → $10 | Upgrade | Neutral → Outperform | Get Alert |
| 05/10/2023 | BDTX | Buy Now | Black Diamond Therapeutic | $4.98 | -39.77% | Wedbush | Robert Driscoll | → $3 | Reiterates | → Neutral | Get Alert |
| 03/29/2022 | BDTX | Buy Now | Black Diamond Therapeutic | $4.98 | — | Wedbush | Robert Driscoll | — | Downgrade | Outperform → Neutral | Get Alert |
| 03/22/2022 | BDTX | Buy Now | Black Diamond Therapeutic | $4.98 | — | HC Wainwright & Co. | Robert Burns | — | Downgrade | Buy → Neutral | Get Alert |
| 03/18/2022 | BDTX | Buy Now | Black Diamond Therapeutic | $4.98 | -19.7% | Stifel | Bradley Canino | $10 → $4 | Maintains | Hold | Get Alert |
| 09/30/2021 | BDTX | Buy Now | Black Diamond Therapeutic | $4.98 | 100.75% | Stifel | Bradley Canino | — | Initiates | → Hold | Get Alert |
FAQ
What is the target price for Black Diamond Therapeutic (BDTX)?
The latest price target for Black Diamond Therapeutic (NASDAQ: BDTX) was reported by Wedbush on April 8, 2024. The analyst firm set a price target for $16.00 expecting BDTX to rise to within 12 months (a possible 221.21% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Black Diamond Therapeutic (BDTX)?
The latest analyst rating for Black Diamond Therapeutic (NASDAQ: BDTX) was provided by Wedbush, and Black Diamond Therapeutic maintained their outperform rating.
When was the last upgrade for Black Diamond Therapeutic (BDTX)?
The last upgrade for Black Diamond Therapeutics Inc happened on June 30, 2023 when Stifel raised their price target to $10. Stifel previously had a hold for Black Diamond Therapeutics Inc.
When was the last downgrade for Black Diamond Therapeutic (BDTX)?
The last downgrade for Black Diamond Therapeutics Inc happened on March 29, 2022 when Wedbush changed their price target from N/A to N/A for Black Diamond Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Black Diamond Therapeutic (BDTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Black Diamond Therapeutic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Black Diamond Therapeutic was filed on April 8, 2024 so you should expect the next rating to be made available sometime around April 8, 2025.
Is the Analyst Rating Black Diamond Therapeutic (BDTX) correct?
While ratings are subjective and will change, the latest Black Diamond Therapeutic (BDTX) rating was a maintained with a price target of $10.00 to $16.00. The current price Black Diamond Therapeutic (BDTX) is trading at is $4.98, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.